Sun Pharma Advanced Research Co Debt/EBITDA

What does Sun Pharma Advanced Research Co do? Sun Pharma Advanced Research Co Ltd develops pharmaceutical products for unmet medical needs in oncology, neurodegeneration, and immunology. The company focuses on New Chemical Entities (NCEs) such as SCC-138, SCO-088, SCO-120, and SCD-044, as well as Novel Drug Delivery Systems (NDDS) including Wrap Matrix Technology for controlled release tablets. Elepsia XR, developed using Wrap MatrixTM, is a commercialized product, while Xelpros, a BAK-free latanoprost eye drop based on Lipexelle technology, is marketed by a U.S. partner. The company also created PDP-716 eye drops for glaucoma treatment using TearAct technology. The firm generates revenue through R&D partnerships and commercialization of its drug candidates. Elepsia XR and Xelpros are sold under licensing agreements, with Xelpros marketed in the U.S. by a partner. PDP-716 is positioned for glaucoma treatment, leveraging TearAct technology. The company’s products target medical segments requiring innovative solutions, such as controlled-release formulations and eye care, with a focus on oncology, neurodegeneration, and immunology. Sun Pharma Advanced Research Co Ltd’s revenue streams include licensing agreements for its NCEs and NDDS technologies. Partners in the U.S. commercialize Xelpros, while Elepsia XR is sold directly. The company’s R&D pipeline, including SCC-138 and PDP-716, supports future revenue potential. Its focus on unmet medical needs drives partnerships with pharmaceutical firms seeking innovative drug delivery solutions. Sun Pharma Advanced Research Co is one of the most popular companies on Eulerpool.